Table 1

Storage possibilities in 2015 and the future applying logarithmic dose banding of intravenous anticancer drug preparations with usage data of 2015 in a tertiary care hospital

INNSituation in 2015
No. of individual prescriptions in 2015
per product
(n=21 164)
Real-life storage
No. of
DB strengths in 2015
(n=25)
Future storage
No. of potential DB strengths per year
(n=85)
Maximal future storage
No. of
DB preparations
(n=21 164)
Safe future storage
No. of
DB preparations
 (n=21 164)
Shelf life under specific conditions
in days ref
Bevacizumab66509554333907
Carboplatin1045012752368567 8
Cisplatin105507535182287
Docetaxel354021447828*
Epirubicin4060437321784*
5-Fluorouracil
infusion bag
1957 5 5 94960028*
pump1038 3 6 1466978
Gemcitabine8305977546584*
Irinotecan69105494273287
Methotrexate11080252138456*
Oxaliplatin762 4 5 537286149
Paclitaxel2218561926106914*
Pemetrexed16203133483110
Rituximab600 3 5 5523489011
Trastuzumab108904101992018012
Vincristine9340142731377
Summation DB, n (% of all individual prescriptions)5292 (25.0)NANA11 157 (52.7)6862 (32.4)
Summation preparations NOT DB, n (% of all individual prescriptions)15 872 (75.0)NANA10 007 (47.3)14 302 (67.6)
  • *Data obtained from manufacturer.

  • DB , dose band; INN, International non-proprietary name; NA, not applicable.